Journal of Internal Medicine Concepts & Practice >

2025 , Vol. 20 >Issue 05: 410 - 414

DOI: https://doi.org/10.16138/j.1673-6087.2025.05.12

Renal manifestations of rheumatic autoimmune diseases

  • ZHANG Xiaoyan ,
  • LI Huilin
Expand
  • 1. Department of Nephrology and Rheumatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200093, China
    2. Department of Nephrology / Rheumatology and Immunology, Shanghai Pudong Gongli Hospital, Shanghai 200135, China

Received date: 2024-11-20

  Online published: 2025-12-26

Copyright

, 2025, Copyright reserved © 2025.
Fold

Abstract

Rheumatic autoimmune diseases are characterized by the involvement of multiple systems and organs, and the kidney is a common and critical target. The clinical manifestations of kidney diseases caused by different rheumatic diseases are diverse, ranging from asymptomatic hematuria and proteinuria to rapidly progressive glomerulonephritis and renal failure, and vary in severity. The treatment strategies and prognosis differ depending on the specific clinical manifestation. This article reviews relevant domestic and international literature, summarizing the renal manifestations associated with common rheumatic diseases. The aim is to improve clinicians’ understanding of the diseases, enabling them to intervene early to improve patient outcomes.

Key words： Rheumatic autoimmune diseases; Tubulointerstitial nephritis; Glomerulonephritis; Epidemiology

Cite this article

ZHANG Xiaoyan , LI Huilin . Renal manifestations of rheumatic autoimmune diseases[J]. Journal of Internal Medicine Concepts & Practice, 2025 , 20(05) : 410 -414 . DOI: 10.16138/j.1673-6087.2025.05.12

References

[1] Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study[J]. Rheumatology (Oxford), 2016, 55(2): 252-262.
[2] Mohan C, Zhang T, Putterman C. Pathogenic cellular and molecular mediators in lupus nephritis[J]. Nat Rev Nephrol, 2023, 19(8): 491-508.
[3] Parodis I, Rovin BH, Tektonidou MG, et al. Lupus nephritis[J]. Nat Rev Dis Primers, 2025, 11(1): 69.
[4] Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression[J]. Lupus, 2020, 29(9): 1011-1020.
[5] Gisca E, Duarte L, Farinha F, et al. Assessing outcomes in a lupus nephritis cohort over a 40-year period[J]. Rheumatology (Oxford), 2021, 60(4): 1814-1822.
[6] Saxena R. Predicting kidney survival in lupus nephritis by adding clinical data to pathologic features[J]. Kidney360, 2022, 3(1): 5-7.
[7] Gasparotto M, Gatto M, Binda V, et al. Lupus nephritis: clinical presentations and outcomes in the 21st century[J]. Rheumatology (Oxford), 2020, 59(Suppl 5): v39-v51.
[8] Vazzana KM, Daga A, Goilav B, et al. Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort[J]. Lupus, 2021, 30(10): 1660-1670.
[9] Yap DYH, Xu X, Juliao PC, et al. Long-term kidney outcome of lupus nephritis by renal response status[J]. Kidney Int Rep, 2024, 9(12): 3532-3541.
[10] Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: Core Curriculum 2020[J]. Am J Kidney Dis, 2020, 76(2): 265-281.
[11] Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update[J]. Ann Rheum Dis, 2024, 83(1): 15-29.
[12] Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices [J]. Kidney Int, 2018, 93(4): 789-796.
[13] Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis[J]. Nat Rev Dis Primers, 2020, 6(1): 7.
[14] Parodis I, Adamichou C, Aydin S, et al. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis[J]. Rheumatology (Oxford), 2020, 59(11): 3424-3434.
[15] Louis Sam Titus ASC, Tan Y, Tran P, et al. Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics[J]. Clin Immunol, 2023, 254: 109713.
[16] Paul M, Addya S, Sengupta M, et al. Spectrum of renal vascular lesions among patients with lupus nephritis: an experience from a tertiary care center[J]. Indian J Pathol Microbiol, 2023, 66(4): 751-757.
[17] Xia W, Deng J, Zhuang L, et al. Risk factors for acute kidney injury and kidney relapse in patients with lupus podocytopathy[J]. Clin Kidney J, 2024, 17(6): sfae148.
[18] Jasiek M, Karras A, Le Guern V, et al. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sj?gren's syndrome [J]. Rheumatology (Oxford), 2017, 56(3): 362-370.
[19] Yang HX, Wang J, Wen YB, et al. Renal involvement in primary Sj?gren's syndrome: A retrospective study of 103 biopsy-proven cases from a single center in China[J]. Int J Rheum Dis, 2018, 21(1): 223-229.
[20] Chatterjee R, Balakrishnan A, Kharbanda R, et al. Renal involvement in Sj?gren's syndrome: predictors and impact on patient outcomes[J]. Rheumatol Int, 2023, 43(7): 1297-1306.
[21] Aiyegbusi O, McGregor L, McGeoch L, et al. Renal disease in primary Sjogren’s syndrome[J]. Rheumatol Ther, 2021, 8(1): 63-80.
[22] Maleki-Fischbach M, Kastsianok L, Koslow M, et al. Manifestations and management of Sjogren's disease[J]. Arthritis Res Ther, 2024, 26(1): 43.
[23] Brito-Zerón P, Acar-Denizli N, Ng WF, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sj?gren's syndrome[J]. Rheumatology (Oxford), 2020, 59(9): 2350-2359.
[24] Trevisani VFM, Pugliesi A, Pasoto SG, et al. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal)[J]. Adv Rheumatol, 2022, 62(1): 18.
[25] Luo J, Xu S, Lv Y, et al. Clinical features and potential relevant factors of renal involvement in primary Sjogren’s syndrome[J]. Int J Rheum Dis, 2019, 22(2): 182-190.
[26] Baldini C, Fulvio G, La Rocca G, et al. Update on the pathophysiology and treatment of primary Sjogren syndrome[J]. Nat Rev Rheumatol, 2024, 20(8): 473-491.
[27] Goules A, Geetha D, Arend LJ , et al. Renal involvement in primary Sj?gren’s syndrome:natural history and treatment outcome [J]. Clin Exp Rheumatol, 2019, 37 Suppl 118(3):123-132.
[28] Hanberg JS, Cook C, Fu X, et al. Longitudinal patterns of renal function in antineutrophil cytoplasmic antibody-associated vasculitis[J]. Arthritis Care Res (Hoboken), 2023, 75(10): 2190-2198.
[29] Guo Q, Yu L, Zhang X, et al. Analysis of the risk factors for end-stage renal disease and mortality in ANCA-associated vasculitis: a study from a single center of the Chinese Rheumatism Data Center[J]. Clin Rheumatol, 2023, 42(2): 489-499.
[30] Trivioli G, Gopaluni S, Urban ML, et al. Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome[J]. Clin Kidney J, 2020, 14(1): 332-340.
[31] Christodoulou M, Moysidou E, Lioulios G, et al. The prognostic value of two histopathologic classification models of ANCA-associated glomerulonephritis: a prospective study[J]. J Nephrol, 2024, 37(4): 941-950.
[32] Boud'hors C, Copin MC, Wacrenier S, et al. Histopathological prognostic factors in ANCA-associated glomerulonephritis[J]. Autoimmun Rev, 2022, 21(9): 103139.
[33] Hudson M, Ghossein C, Steen V. Scleroderma renal crisis[J]. Presse Med, 2021, 50(1): 104063.
[34] 莫颖倩, 严青, 叶霜, 等. 未分化结缔组织病和混合性结缔组织病的诊疗规范[J]. 中华内科杂志, 2022, 61(10): 1119-1127.
  Mo YQ, Yan Q, Ye S, et al. Standardized diagnosis and treatment of undifferentiated connective tissue disease and mixed connective tissue disease[J]. Chin J Intern Med, 2022, 61(10): 1119-1127.
[35] Madieh J, Khamayseh I, Hrizat A, et al. Scleroderma renal crisis in a case of mixed connective tissue disease treated successfully with angiotensin-converting enzyme inhibitors [J]. Case Rep Nephrol, 2021, 2021: 8862405.
[36] Kawano M, Saeki T, Ubara Y, et al. Recent advances in IgG4-related kidney disease [J]. Mod Rheumatol, 2023, 33(2): 242-251.
[37] 黄烽, 朱剑, 王玉华, 等. 强直性脊柱炎诊疗规范[J]. 中华内科杂志, 2022, 61(8): 893-900.
  Huang F, Zhu J. Wang YH, et al. Recommendations for diagnosis and treatment of ankylosing spondylitis [J]. Chin J Intern Med, 2022, 61(8): 893-900.
Options
Outlines

/

〈 〉